The Heart of the Matter

Barbara is 72 and sitting in a paper gown on an exam table when her doctor tells her that her blood pressure is “a little high.” Her cholesterol is borderline. Her EKG looks fine. She has eight minutes left in this appointment.

In those eight minutes, her doctor will weigh a statin prescription against the possibility that it will cause muscle pain severe enough to keep Barbara from walking her neighborhood loop every morning. He will consider pushing her blood pressure target lower, knowing that the medication needed to get there may make her dizzy enough to fall. He will not have time to explain why the 70-year-old heart sitting in her chest, perfectly healthy by every standard measure, still works differently than it did at 50. He will not have time to explain what that difference means, or what is modifiable and what is not.

This is not a failure of her doctor. It is a failure of the system that gives him eight minutes.

What Changes in the Aging Heart

Even in the absence of disease, the cardiovascular system changes with age in specific, measurable ways. The large arteries stiffen. The walls of the left ventricle thicken slightly, compensating for the increased effort of pumping blood through less compliant vessels. Cardiac output at rest may remain adequate, but the heart’s reserve capacity declines, meaning it cannot ramp up as efficiently during exertion or stress. Heart valves accumulate calcium deposits. The electrical conduction system slows, making arrhythmias more common.

None of this is disease. All of it creates vulnerability. A 70-year-old heart that has never been sick still works differently than a 40-year-old heart. The question is not whether it is aging. The question is what remains modifiable and what does not.

This distinction matters because it determines what is worth worrying about and what is worth doing something about. Arterial stiffening is partly genetic, partly the cumulative result of decades of blood pressure, blood sugar, and inflammation. The genetic component you cannot change. The cumulative damage you can slow. That slowing is the entire premise of cardiovascular medicine in older adults, and it is a premise supported by decades of evidence.

The Numbers That Matter

Heart disease remains the leading cause of death in Americans over 65. According to the AHA’s 2026 Heart Disease and Stroke Statistics, cardiovascular conditions account for roughly one in four deaths in the United States, with the burden concentrated heavily among older adults. Total direct and indirect annual costs for cardiovascular disease and stroke in patients 65 and older exceed $174 billion, representing about 42 percent of all cardiovascular spending in the country.

Those numbers have been declining for decades. Age-adjusted mortality from heart attack dropped more than 60 percent between 1999 and 2019, a remarkable achievement driven by statins, blood pressure control, emergency cardiac intervention, and public awareness campaigns. But the decline has plateaued, and in some populations it is reversing. Heart failure prevalence is rising, projected to reach 11.4 million Americans by 2050, up from 6.7 million today. And the improvements have not been shared equally.

Black Americans have the highest age-adjusted cardiovascular mortality of any racial group. Heart failure mortality among Black individuals has risen faster than in any other group over the past decade. Women present with cardiovascular disease differently than men, are diagnosed later, and have worse outcomes. The average age at first heart attack is 65.6 for men and 72.0 for women, a gap that reflects hormonal protection during reproductive years and its abrupt loss at menopause. Geography matters too: the Southeast “stroke belt” remains a region of concentrated cardiovascular death, and rural Americans face longer travel times to cardiac catheterization labs and fewer cardiologists per capita.

These disparities are not biological curiosities. They are the result of structural differences in access, treatment, and the social determinants that shape cardiovascular risk across a lifetime.

The Statin Question

If you are over 65, someone has either prescribed you a statin or talked to you about one. The conversation often lasts less than two minutes. It deserves more.

For adults 40 to 75 with known cardiovascular disease or high risk factors, the evidence for statins is clear: moderate to high intensity statin therapy reduces cardiovascular events. This is not controversial. For every 1 mmol/L reduction in LDL cholesterol, major vascular events drop by roughly 22 percent, a finding replicated across dozens of trials.

The picture gets murkier after 75. Most major statin trials enrolled patients between 40 and 75, which means the evidence base for older adults, particularly those without existing heart disease, is thinner. A 2024 target trial emulation study in the Annals of Internal Medicine found that starting a statin in adults 75 to 84 produced a modest but real 1.2 percent absolute risk reduction for cardiovascular events over five years. For adults 85 and older, the reduction was 4.4 percent in intention-to-treat analysis. A joint 2025 consensus statement from the National Lipid Association and the American Geriatrics Society concluded that statin initiation may be reasonable for primary prevention in adults over 75 with elevated LDL and no life-limiting illness, particularly when coronary artery calcium scoring shows significant buildup.

What none of these guidelines adequately address is the trade-off calculus that Barbara’s doctor is running in his head during those eight minutes. Statins can cause muscle symptoms. In a 35-year-old, sore muscles are an inconvenience. In a 72-year-old who walks every morning and whose mobility is her independence, muscle pain that stops her walking may cause more harm than the cardiovascular event the statin was meant to prevent. This is not an argument against statins. It is an argument for the conversation that most clinical encounters do not have time to hold.

If you are over 75, taking a statin, and tolerating it well, the consensus is clear: do not stop. A large French study found that adults 75 and older who discontinued statins had a 33 percent higher risk of cardiovascular hospitalization. Stopping a statin that is working is riskier than continuing one that is causing no problems.

The Blood Pressure Targets Debate

The SPRINT trial, published in 2015, changed blood pressure management. It showed that targeting a systolic pressure below 120 mm Hg, rather than the traditional 140, reduced cardiovascular events by 25 percent and all-cause mortality by 27 percent. Among participants 75 and older, the benefits were at least as large: primary outcome events dropped from 11.2 percent to 7.7 percent.

But those benefits came with costs. Patients in the intensive treatment group experienced more episodes of low blood pressure, more fainting, more electrolyte abnormalities, and more acute kidney injury. For an older adult already taking five or six medications, adding another blood pressure pill (the intensive group averaged three medications versus two) increases the polypharmacy load that Series 3’s later installments will examine in detail.

A 2025 individualized analysis of SPRINT participants over 65, published in the Journal of the American Geriatrics Society, found that nearly all community-dwelling older adults had a positive net benefit from intensive blood pressure lowering, including those who were frail or taking multiple medications. But the word “community-dwelling” matters. SPRINT excluded people in nursing homes, people with dementia, and people with a life expectancy under three years. The real-world population of older adults with hypertension is broader and more complicated than what SPRINT enrolled.

The honest answer, and the one most guidelines now reflect, is that blood pressure targets in older adults should be individualized. A healthy 72-year-old who tolerates medications well may benefit from a target below 130. A frail 85-year-old who has fallen twice in the past year from dizziness may be harmed by the same target. The question is whether the appointment is long enough to figure out which patient is which.

Where Technology Enters

AI-driven cardiovascular risk models are beginning to outperform the traditional Framingham scoring system, which was developed decades ago using a largely white, suburban population. Newer models integrate data from electronic health records, social determinants of health, retinal imaging, and ECG patterns to produce more accurate, more individualized risk estimates. A 2025 study showed that deep learning algorithms can predict cardiac biological age from echocardiograms, identifying patients whose hearts are aging faster than their chronological age would suggest, potentially flagging risk before clinical symptoms appear.

Remote cardiac monitoring is also maturing. A 2026 study in European Heart Journal Digital Health showed that primary care patients using a remote cardiovascular monitoring system sustained blood pressure improvements at 12 months, a duration that matters because short-term improvements often fade. AI-enabled digital stethoscopes are improving detection of valvular disease in primary care settings where many patients never see a cardiologist.

The honest assessment: these tools are improving detection and risk stratification. But access is uneven, validation across diverse and elderly populations remains incomplete, and the infrastructure for deploying AI-assisted cardiovascular care in a typical community clinic rather than an academic medical center is thin.

The ACCESS model, a CMS innovation initiative launching in July 2026, will create the first dedicated Medicare payment pathway for continuous remote monitoring of hypertension and cardiovascular disease. If it works as designed, it could begin closing the gap between what the technology can do and what patients actually receive. It is a pilot, not a guarantee.

The Conversation at the Kitchen Table

Here is what this means for the person sitting across the breakfast table, taking a blood pressure reading before the coffee is ready.

Some of what is happening in your cardiovascular system is the simple arithmetic of time. Arteries stiffen. Valves calcify. The heart adapts, and adaptation has limits. This is not failure. It is biology.

But a great deal of cardiovascular risk in older adults is modifiable: blood pressure, blood sugar, cholesterol, physical activity, body weight, smoking. The evidence on each is not speculative. It is among the most thoroughly studied terrain in all of medicine.

The statin conversation, the blood pressure target conversation, the medication review that weighs every pill against every risk: these are conversations worth having, fully, with a clinician who knows your complete picture. If your appointment does not feel long enough for that conversation, it probably is not. Ask for a longer one. Bring your medication list. Bring your questions.

And know this: the single most powerful cardiovascular intervention available to you does not require a prescription, an insurance code, or an AI algorithm. It requires getting up and moving. How and why will be the subject of this series’ final installment. But the cardiovascular case for exercise is not a pep talk. It is arithmetic, and the numbers are overwhelming.

This is the first installment of “The Body After 60.” Next: the metabolic condition that accelerates everything else.